

DAFTAR PUSTAKA

1. WHO. Global guidelines for the prevention of surgical site infection. *J Hosp Infect.* 2017;95(2):135–6.
2. Marni H, Djanas D. Pola Bakteri dan Sensitivitasnya Terhadap Antibiotik pada Pasien Rawat Inap Bagian Obstetri dan Ginekologi RSUP Dr. M. Djamil Padang pada Bulan Mei 2017-Mei 2018. Universitas Andalas; 2018.
3. Oliphant SS, Jones KA, Wang L, Bunker CH, Lowder JL. Trends Over Time With Commonly Performed Obstetric and Gynecologic Inpatient Procedure. *NIH Public Acces.* 2010;116(4):926–31.
4. Aditya R. Faktor Risiko Infeksi Luka Operasi Bagian Obstetri dan Ginekologi RSUD Ulin Banjarmasin. *J Berk Kesehat.* 2018;4(1):10–7.
5. World Health Organization. WHO Statement on Caesarean Section Rates. In Geneva: WHO; 2015. Available from: <https://www.who.int/reproductivehealth/en/>
6. Betrán AP, Ye J, Miller AB, Zhang J, Gülmezoglu AM, Torloni MR. The increasing trend in caesarean section rates: Global, regional and national estimates: 1990-2014. *PLoS One.* 2016;11(2):1–12.
7. Putri ET, Herdayati M. Persalinan dengan Metode Operasi Sesar di Indonesia dan Faktor yang Mempengaruhi. Jakarta; 2014.
8. Litbangkes Kementerian RI. Laporan Nasional RISKESDAS 2018. 2018.
9. Center for Disease Control and Prevention. Procedure-associated Module SSI (Surgical Site Infection). 2019.
10. American College of Obstetricians and Gynecologists. Clinical Management Guidelines for Obstetricians & Gynecologists-Use of Prophylactic Antibiotics in Labor and Delivery. In: *Obstetrics & Gynecology.* Washington DC: ACOG; 2018. p. 103–19.
11. American College of Obstetricians and Gynecologists. Clinical Management Guidelines for Obstetricians & Gynecologists-Prevention of Infection After Gynecologic Procedures. In: *Obstetrics & Gynecology.* Washington DC: ACOG; 2018. p. 172–89.

12. Pathak A, Mahadik K, Swami MB, Roy PK, Sharma M, Mahadik VK, et al. Incidence and risk factors for surgical site infections in obstetric and gynecological surgeries from a teaching hospital in rural India. *Antimicrob Resist Infect Control*. 2017;6(66):1–8.
13. Gevariya R, Oza H, Doshi H, Parikh P. Epidemiology, Risk Factors and Outcome of Complications in Obstetric and Gynecological Surgeries — A Tertiary Center Experience from Western India. *J US-China Med Sci*. 2015;12:45–52.
14. Van Schalkwyk J, Van Eyk N. Antibiotic Prophylaxis in Obstetric Procedures. *J Obstet Gynaecol Canada*. 2017;39(9):e293–9.
15. Perkumpulan Obstetri Ginekologi Indonesia. Panduan Antibiotika Profilaksis Pada Pembedahan Obstetri dan Ginekologi. Jakarta; 2013.
16. Hamidy MY, Fauzia D, Nugraha DP, Muttaqien MI. Penggunaan Antibiotik Profilaksis Bedah pada Sectio Cesarea di RSUD Arifin Achmad Provinsi Riau. *JIK*. 2016;10(1):33–7.
17. Muzayyanah B, Yulistiani Y, Hasmono D, Wisudani N. Analysis of Prophylactic Antibiotic Usage in Caesarean Section Delivery. *Folia Medica Indones*. 2013;4(3):161–6.
18. Husnawati, Wandasari F. Pola Penggunaan Antibiotik Profilaksis pada Pasien Bedah Caesar di Rumah Sakit Pekanbaru Medical Center (PMC) Tahun 2014. *J Sains Farm Klin*. 2016;2(2):303–7.
19. Kusaba T. Safety and Efficacy of Cefazolin Sodium in the Management of Bacterial Infection and in Surgical Prophylaxis. *Clin Med Ther*. 2009;1607–15.
20. Marathias SGK, Kadas JKB. Cephalosporins in Surgical Prophylaxis. *J Chemother*. 2001;13(1):23–6.
21. Mehta D, Sharma AK. Cephalosporins: A Review on Imperative Class of Antibiotics. *Inven Rapid Mol Pharmacol*. 2015;2016(1):1–6.
22. Masoud MS, Ali AE, Nasr NM. Chemistry, classification, pharmacokinetics, clinical uses and analysis of beta lactam antibiotics : A review. *J Chem Pharm Res*. 2014;6(11):28–58.
23. PT Askes. Keputusan Direksi PT Askes (Persero) Nomor 378 Tahun 2012.

- 2012.
24. RSUP Dr. M. Djamil. Panduan Penggunaan Antibiotik RSUP Dr. M. Djamil Padang. Indonesia; 2018.
25. Etebu E, Arikekpar I. Antibiotics: Classification and mechanisms of action with emphasis on molecular perspectives. *Int J Appl Microbiol Biotechnol Res.* 2016;4:90–101.
26. Ganiswara S. *Farmakologi dan Terapi*. 5th ed. Jakarta: Departemen Farmakologi dan Terapeutik Fakultas Kedokteran Universitas Indonesia; 2007.
27. Gallagher J. *Antibiotics Simplified*. 4th ed. United States: Jones & Barlett Learning; 2018.
28. Levison ME, Levison JH. Pharmacokinetics and Pharmacodynamics of Antibacterial Agents. *Infect Dis Clin North Am.* 2009;23(4):791–815.
29. Eyler RF, Shvets K. Clinical Pharmacology of Antibiotics. *Clin J Am Soc Nephrol.* 2019;14.
30. Carroll KC, Morse SA, Mietzner T, Miller S, Jawetz, Melnick & Alderberg's *Medical Microbiology*. 27th ed. United States: McGraw Hill Education; 2016.
31. Black JG, Black LJ. *Microbiology: Principles and Explorations*. 9th ed. United States: Wiley; 2015.
32. Gualerzi CO, Brandi L, Fabbretti A, Pon CL. *Antibiotics: Target, Mechanisms, and Resistance*. Germany: Wiley-VCH; 2014.
33. Yuson CL, Katelaris CH, Smith WB. Cephalosporin allergy label is misleading. *Aust Prescr.* 2018;41(2):37–41.
34. Shahbaz K. Cephalosporins: pharmacology and chemistry. *Pharm Biol Eval.* 2017;4(6):234–8.
35. Perry TR, Schentag JJ. Clinical Use of Ceftriaxone: A Pharmacokinetic-Pharmacodynamic Perspective on the Impact of Minimum Inhibitory Concentration and Serum Protein Binding. *Clin Pharmacokinet.* 2001;40(9):685–94.
36. Skold O. *Antibiotics and Antibiotic Resistance*. Canada: Wiley; 2011.
37. Lestari ES. *Antimicrobial Resistance in Indonesia*. University Medical

- Center, Rotterdam; 2009.
38. Rostina, Rusli B, Arief M, Hardjoeno. Pola Kuman Berdasarkan Spesimen Dan Sensitivitas Terhadap Antimikroba. *Indones J Clin Pathol Med Lab.* 2006;13(1):13–6.
 39. Refdanita, Maksum R, Nurgani A, Endang P. Pola kepekaan kuman terhadap antibiotika di ruang rawat intensif Rumah Sakit Fatmawati Jakarta tahun 2001-2002. *Makara Kesehat.* 2004;8(2):41–8.
 40. Samuel A, Warganegara E. Pola Resistensi Bakteri Aerob Penyebab Infeksi Luka Operasi Terhadap Antibiotik di Ruang Rawat Inap Bagian Bedah dan Kebidanan RSUD Dr. H. Abdul Moeloek Bandar Lampung. *Med J Lampung Univ.* 2012;1:1–16.
 41. Erikawati D, Santosaningsih D, Santoso S. Tingginya Prevalensi MRSA pada Isolat Klinik Periode 2010-2014 di RSUD Dr. Saiful Anwar Malang, Indonesia. *J Kedokt Brawijaya.* 2016;29(2):149–56.
 42. Nismawati, Syahril R, Agus R. Deteksi MRSA pada Pasien Rumah Sakit Universitas Hasanudin dengan Metode Kultur. [Makassar]: Universitas Alauddin; 2018.
 43. Abdel-Maksoud M, El-Shokry M, Ismail G, Hafez S, El-Kholy A, Attia E, et al. Methicillin-Resistant *Staphylococcus aureus* Recovered from Healthcare- and Community-Associated Infections in Egypt. *Int J Bacteriol.* 2016;
 44. Haysom L, Cross M, Anastasas R, Moore E, Hampton S. Prevalence and Risk Factors for Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infections in Custodial Populations: A Systematic Review. *J Correct Heal Care.* 2018;24(2):197–213.
 45. Ierapio, C, Manski-Nankervis JA, James R, Rajkhowa A, Peel T, Thursky K. Surgical antimicrobial prophylaxis. *Aust Prescr.* 2017;40(6):225–9.
 46. Young PY, Khadaroo RG. Surgical Site Infections. *Surg Clin North Am.* 2014;94:1245–64.
 47. Zuarez-Easton S, Zafran N, Garmi G, Salim R. Postcesarean wound infection: Prevalence, impact, prevention, and management challenges. *Int J Womens Health.* 2017;9:81–8.

48. Ban KA, Minei JP, Laronga C, Harbrecht BG, Jensen EH, Fry DE, et al. American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. *J Am Coll Surg.* 2017;224(1):59–74.
49. Asia Pacific Society of Infection Control. The APSIC Guidelines for The Prevention of Surgical Site Infections [Internet]. APSIC; 2018. Available from: <http://apsic-apac.org/wp-content/uploads/2017/01/APSIC-SSI-Prevention-guideline-June-2018.pdf>
50. Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. *Nat Rev Immunol.* 2015;15(6):335–49.
51. Narayan M, Medinilla SP. Fever in the Postoperative Patient. *Emerg Med Clin North Am.* 2013;31:1045–58.
52. Heredia-Rodriguez M, Bustamante-Munguira J, Lorenzo M, Gomez-Sanchez E, Alvarez J, Fierro I, et al. Procalcitonin and white blood cells, combined predictors of infection in cardiac surgery patients. *J Surg Res.* 2017;7(212):187–94.
53. Nagano S, Yokouchi M, Setoguchi T, Sasaki H, Shimada H, Kawamura I, et al. Analysis of Surgical Site Infection after Musculoskeletal Tumor Surgery : Risk Assessment Using a New Scoring System. *Hindawi Publ Corp.* 2014;1–10.
54. Hirshberg JS, Tuuli MG, Stout MJ, Conner SN, Lopez JD, Macones GA, et al. What is the threshold of maternal leukocytosis in labor associated with maternal or neonatal morbidity? *Am J Obstet Gynecol.* 2017;216(1).
55. National Institute for Health and Care Excellence. Surgical site infections: prevention and treatment [Internet]. NICE guideline; 2019. Available from: <https://www.nice.org.uk/guidance/cg74/resources/surgical-site-infections-prevention-and-treatment-975628422853>
56. Najjar PA, Smink DS. Prophylactic Antibiotics and Prevention of Surgical Site Infections. *Surg Clin North Am.* 2015;95(2):269–83.
57. Singh R, Singla P, Chaudhary U. Surgical Site Infections : Classification , Risk factors , Pathogenesis and Preventive Management. *Int J Pharma Res*

- Heal Sci. 2014;2(3):203–14.
58. Azar FM, Beaty JH, Canale ST. Campbell's Operative Orthopaedics. 13th ed. Daugherty K, Jones L, editors. Philadelphia: Elsevier; 2017. 744–745 p.
59. Rohilla M, Muthyala T, Aggarwal S. Review of recommendations on prophylactic antibiotic use in cesarean section-A Review Article. *J Gynecol Neonatal Biol.* 2018;4(1):18–21.
60. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Nomor 8 Tahun 2015 tentang Program Pengendalian Resistensi Antimikroba. Jakarta; 2015.
61. Karlatti S, Havannavar I. A comparative prospective study of preoperative antibiotic prophylaxis in the prevention of surgical site infections. *Int Surg J.* 2016;3(1):141–5.
62. Bratzler DW, Dellinger EP, Olsen KM, Peri TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Heal Pharm.* 2013;70:195–283.
63. Berriós-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, et al. Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. *JAMA Surg.* 2017;152(8):784–91.
64. Quinlan JD, Murphy NJ. Cesarean delivery: counseling issues and complication management. *Am Fam Physician.* 2015;91(3):178–84.
65. Eljaaly K, Alshehri S, Erstad BL. Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin. *Am Soc Microbiol.* 2018;62(4):1–10.
66. Ho VP, Nicolau DP, Dakin GF, Pomp A, Rich BS, Towe CW, et al. Cefazolin Dosing for Surgical Prophylaxis in Morbidly Obese Patients. *Surg Infect (Larchmt).* 2012;13(1):33–7.
67. Rahmansyah A, Hakimi M, Siswishanto R. Perbandingan Antara Pemberian Antibiotika Profilaksis Pada Seksio Sesar Sesuai Alur Klinis Rsup Dr Sardjito Dengan Antibiotika Dosis Multipel Terhadap Kejadian Infeksi Luka Operasi. *J Kesehat Reproduksi.* 2018;3(2):75–83.
68. Khakhkhar T, Shah R, Hemavathi KG. Current status of post-operative

- antibiotic prophylaxis in surgical wards. *Natl J Physiol Pharm Pharmacol*. 2016;6(6):622–6.
69. Bizimana K, Ndoli J, Bayingana C, Baluhe I, Gilson GJ, Habimana E. Prevalence and Risk Factors for Post Cesarean Delivery Surgical Site Infection in a Teaching Hospital Setting in Rural Rwanda: A Prospective Cross Sectional Study. *Int J Curr Microbiol Appl Sci*. 2016;5(6):631–41.
70. Jasim SK. Post-Cesarean Section Surgical Site Infection: Incidence and Risk Factors. *Int J Sci Res*. 2017;6(7):1864–8.
71. Dahlke JD, Mendez-Figueroa H, Rouse DJ, Berghella V, Baxter JK, Chauhan SP. Evidence-based surgery for cesarean delivery: An updated systematic review. *Am J Obstet Gynecol*. 2013;209(4):294–306.
72. Thelwall S, Harrington P, Sheridan E, Lamagni T. Impact of obesity on the risk of wound infection following surgery: Results from a nationwide prospective multicentre cohort study in England. *Clin Microbiol Infect* [Internet]. 2015;21(11):1008.e1-1008.e8. Available from: <http://dx.doi.org/10.1016/j.cmi.2015.07.003>
73. Agodi A, Quattrocchi A, Barchitta M, Adornetto V, Cocuzza A, Latino R, et al. Risk of surgical site infection in older patients in a cohort survey: Targets for quality improvement in antibiotic prophylaxis. *Int Surg*. 2015;100(3):473–9.
74. Assawapalangool S, Kasatpibal N, Sirichotiyakul S, Arora R, Suntornlimsiri W, Apisarnthanara. The efficacy of ampicillin compared with ceftriaxone on preventing caesarean surgical site infection: an observational prospective cohort study. *Antimicrob Resist Infect Control*. 2018;22(7):1–8.
75. Chiu G, Su L, Huang Y, Lai J, Chen H, Wu T, et al. Increasing Ceftriaxone Resistance and Multiple Alterations of Penicillin-Binding Proteins among Penicillin-Resistant *Streptococcus pneumoniae* Isolates in Taiwan □. 2007;51(9):3404–6.
76. Muller A, Bertrand X, Talon D. Relationship between ceftriaxone use and resistance to third-generation cephalosporin among clinical strains of *E. cloacae*. *J Antimicrob Chemother*. 2004;54(1):173–7.

77. Shalviri G, Yousefian S, Gholami K. Adverse events induced by ceftriaxone : a 10-year review of reported cases to Iranian Pharmacovigilance Centre. *J Clin Pharm Ther.* 2011;1–4.
78. Su H, Ding D, Chen D, Lu M, Liu J. Prospective randomized comparison of single- dose versus 1-day cefazolin for prophylaxis in gynecologic surgery Prospective randomized comparison of single-dose versus 1-day cefazolin for prophylaxis in gynecologic surgery. *Acta Obst Gynecol Scand.* 2005;84:384–9.
79. Unger NR, Stein BJ. Effectiveness of Pre-Operative Cefazolin in Obese Patients. *Surg Infect (Larchmt).* 2014;15(4):412–6.
80. Kanayama M, Hashimoto T, Shigenobu K, Oha F, Togawa D. Effective prevention of surgical site infection using a Centers for Disease Control and Prevention guideline–based antimicrobial prophylaxis in lumbar spine surgery. *J Neurosurg Spine.* 2007;6:327–9.
81. Zeller V, Durand F, Kitzis M, Lhotellier L, Ziza J, Mamoudy P, et al. Continuous Cefazolin Infusion To Treat Bone and Joint Infections : Clinical Efficacy , Feasibility , Safety , and Serum and Bone Concentrations □. *Antimicrob Agentsand Chemother.* 2009;53(3):883–7.
82. Flynt LK, Kenney RM, Zervos MJ. The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin- Susceptible Staphylococcus aureus Bloodstream Infections. *Infect Dis Ther.* 2017;6(2):225–31.
83. WHO. Surgical Site Infection Prevention Guidelines Web Appendix 25. Geneva: World Health Organization; 1999. p. 1–67.
84. Yulia R, Herawati F, Jaelani A, Anggraini W. Evaluasi penggunaan antibiotik dan profil kuman pada seksio sesarea di Rumah Sakit Umum Daerah Kabupaten Pasuruan. *J Farm Klin Indones.* 2018;7(2):69–77.
85. Zejnullahu V, Isjanovska R, Sejfija Z, Zejnullahu V. Surgical site infections after cesarean sections at the University Clinical Center of Kosovo: rates, microbiological profile and risk factors. *BMC Infect Dis.* 2019;19(752):1–9.
86. Kawakita T, Landy H. Surgical site infections after cesarean delivery:

epidemiology, prevention and treatment. *Matern Heal Neonatol Perinatol*. 2017;3(12):1–9.

87. Knight M, Chiochia V, Partlett C, Arias O. Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial. *Lancet*. 2019;393(10189):2395–403.

88. World Health Organization. WHO recommendations non-clinical interventions to reduce unnecessary caesarean section. Geneva: WHO; 2018.

